Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in Non-Cystic Fibrosis Bronchiectasis (MAHALE)
NCT05006573Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of benralizumab in Non-cystic fibrosis bronchiectasis (NCFB), sponsored by AstraZeneca. Started Jul 2021; status: terminated.
02
Drugs
benralizumab
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT05006573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006573.